AstraZeneca: Transforming How New Medicines Flow to Patients Harvard Case Solution & Analysis

David Brennan, CEO of AstraZeneca UK Limited (AZN), was passionate about bringing new medicines to patients. But the industry converting one who showed less patent protection, more competition from generic drugs, more stringent government regulations, reduced productivity in R & D. Strategy? Build a pipeline to the new prescription drugs that were unique enough to provide differentiated benefits for patients, the development of business in the world, streamline the organization and efficiency, as well as a culture of courage, creativity and cooperation. Will the company be able to provide a stable and consistent pipeline of new products at a lower price, most likely, with fewer people? How can a company an average of two new products to the market every year? What areas of R & D company to invest, and that would be R & D conversion look like? "Hide
by Scott Snell, Gerry Yemen Source: Darden School of Business 25 pages. Publication Date: August 16, 2012. Prod. #: UV6507-PDF-ENG

Share This